Rivaroxaban offers effective extended thromboprophylaxis than enoxaparin after THA .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(3):4 Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 242509 patients (>18 yr old) scheduled to undergo elective total hip arthroplasty were randomized to receive either oral rivaroxaban or enoxaparin to compare both methods of thromboprophylaxis. After a 42 day follow up, extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
